# Francesca Cottini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1761724/publications.pdf

Version: 2024-02-01

| 55 | 1,398 | 471509 17 | 330143 37 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 56 | 56 | 56 | 2871 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Rescue of Hippo coactivator YAP1 triggers DNA damageâ€“induced apoptosis in hematological cancers. Nature Medicine, 2014, 20, 599-606. | 30.7 | 250 |
| 2 | Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood, 2012, 120, 3519-3529. | 1.4 | 133 |
| 3 | General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood, 2011, 118, 6618-6625. | 1.4 | 131 |
| 4 | Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia, 2014, 28, 680-689. | 7.2 | 128 |
| 5 | Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13162-13167. | 7.1 | 112 |
| 6 | Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discovery, 2015, 5, 972-987. | 9.4 | 97 |
| 7 | Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research, 2014, 74, 4458-4469. | 0.9 | 63 |
| 8 | Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer Journal, 2015, 5, e312-e312. | 6.2 | 58 |
| 9 | Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia, 2015, 29, 1918-1927. | 7.2 | 55 |
| 10 | Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia, 2017, 31, 645-653. | 7.2 | 47 |
| 11 | Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia, 2013, 27, 2366-2375. | 7.2 | 46 |
| 12 | Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. Cytometry Part B - Clinical Cytometry, 2010, 78B, S61-8. | 1.5 | 43 |
| 13 | p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood, 2017, 129, 1308-1319. | 1.4 | 36 |
| 14 | Anti-tumor activities of selective HSP90Î±/Î² inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia, 2015, 29, 510-514. | 7.2 | 31 |
| 15 | Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics, 2014, 13, 2489-2500. | 4.1 | 23 |
| 16 | Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma. Blood, 2014, 124, 645-645. | 1.4 | 23 |
| 17 | Combination of a Selective HSP90Î±/Î² Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS ONE, 2015, 10, e0143847. | 2.5 | 20 |
| 18 | Novel therapeutic targets in multiple myeloma. Clinical Advances in Hematology and Oncology, 2015, 13, 236-48. | 0.3 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers. Molecular and Cellular Oncology, 2014, 1, e970055. | 0.7 | 9 |
| 20 | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients. Frontiers in Oncology, 2020, 10, 575168. | 2.8 | 8 |
| 21 | Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma. Molecular Cancer Research, 2022, 20, 1083-1095. | 3.4 | 8 |
| 22 | Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. Cancers, 2022, 14, 2277. | 3.7 | 8 |
| 23 | Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy. Methods in Enzymology, 2020, 645, 79-107. | 1.0 | 6 |
| 24 | TAS-117, a Novel Selective Akt Inhibitor Demonstrates Significant Growth Inhibition in Multiple Myeloma Cells in Vitro and in Vivo. Blood, 2012, 120, 942-942. | 1.4 | 5 |
| 25 | Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. Cancer Journal (Sudbury, Mass ), 2013, 19, 263-271. | 2.0 | 4 |
| 26 | G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leukemia and Lymphoma, 2017, 58, 2947-2951. | 1.3 | 4 |
| 27 | Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. Journal of Clinical Medicine, 2020, 9, 3626. | 2.4 | 4 |
| 28 | Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma. Blood, 2018, 132, 1933-1933. | 1.4 | 4 |
| 29 | G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma. Blood, 2016, 128, 5790-5790. | 1.4 | 4 |
| 30 | A novelAPOA1mutation in a patient with renal amyloidosis: unveiling amyloid by next-generation sequencing. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 253-254. | 3.0 | 3 |
| 31 | Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. Blood, 2012, 120, 2932-2932. | 1.4 | 3 |
| 32 | CD56 Has a Critical Role in Regulating Multiple Myeloma Cell Growth and Response to Therapies. Blood, 2021, 138, 889-889. | 1.4 | 3 |
| 33 | Genomics in Multiple Myeloma. , 2014, , 301-319. | | 2 |
| 34 | Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma. Blood, 2011, 118, 2913-2913. | 1.4 | 2 |
| 35 | Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2020, 136, 1-1. | 1.4 | 2 |
| 36 | Functional expression of aryl hydrocarbon receptor as a potential novel therapeutic target in human multiple myeloma. Leukemia and Lymphoma, 2021, 62, 2968-2980. | 1.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL. Blood, 2010, 116, 2440-2440. | 1.4 | 1 |
| 38 | Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma. Blood, 2021, 138, 3796-3796. | 1.4 | 1 |
| 39 | Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells. Blood, 2011, 118, 2920-2920. | 1.4 | 0 |
| 40 | Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma. Blood, 2012, 120, 4023-4023. | 1.4 | 0 |
| 41 | The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma. Blood, 2012, 120, 725-725. | 1.4 | 0 |
| 42 | The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma. Blood, 2013, 122, 3114-3114. | 1.4 | 0 |
| 43 | Antitumor Activities Of An Oral Selective HSP90Î±/Î² Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. Blood, 2013, 122, 4429-4429. | 1.4 | 0 |
| 44 | Synthetic Lethal Approaches to Exploit Replicative Stress in Aggressive Myeloma. Blood, 2014, 124, 173-173. | 1.4 | 0 |
| 45 | Abstract B09: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma.. , 2015, , . | | 0 |
| 46 | Abstract PR04: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma.. , 2015, , . | | 0 |
| 47 | Targeting Replicative Stress to Treat Hematological Disorders. Blood, 2015, 126, 2419-2419. | 1.4 | 0 |
| 48 | Abstract PR13: p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma. , 2017, , . | | 0 |
| 49 | Meta-Analysis Illustrates Role of Interferon-Î³ Signaling in Multiple Myeloma Pathogenesis. Blood, 2018, 132, 4510-4510. | 1.4 | 0 |
| 50 | Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data. Blood, 2019, 134, 4395-4395. | 1.4 | 0 |
| 51 | Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma. Blood, 2019, 134, 5501-5501. | 1.4 | 0 |
| 52 | Interval Progression Serves As a Predictor of Adverse Outcomes in Patients with Multiple Myeloma. Blood, 2021, 138, 3940-3940. | 1.4 | 0 |
| 53 | Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias. Blood, 2021, 138, 2449-2449. | 1.4 | 0 |
| 54 | Targeting the Mitotic Checkpoint in Myeloma with OSU-13, a Novel Mps1/Ttk Inhibitor. Blood, 2021, 138, 2660-2660. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. Frontiers in Oncology, 2022, 12, 858426. | 2.8 | 0 |